TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive Institute Of Medicine Report Says Insurers Should Pay Patient Care Costs In Clinical Trials February 24, 1989